Day One

• Sharing updates from EXL01’s active Phase II trials in gastric cancer, NSCLC, hepatocellular carcinoma, Crohn’s disease, and C. difficile infection
• Present early clinical signals from investigator-led studies, including preliminary data in infection and IBD
• Highlight EXL01’s NOD2-targeted mechanism enabling immune modulation without gut colonisation

• Showcasing species-level insights from COSMOS metagenomics that identify key airway bacteria regulating immune responses
• Presenting experimental data on microbial metabolites, including short-chain fatty acids, and their role in respiratory immunity
• Highlighting the influence of commensal fungi and highlight early examples of phage therapy in respiratory disease

• Presenting preclinical data on a dual-strain LBP for atopic dermatitis that restores skin barrier function and reduces S. aureus colonisation
• Optimising topical formulation strategies and translational plans for dermatology applications in both human and veterinary models
• Introducing a microbiome-based co-therapy to mitigate GLP-1 side effects in obesity treatment while preserving gut barrier integrity

• Unpack microbiome–neuroendocrine pathways that influence inflammation and therapeutic efficacy
• Assess the effects of gut–brain signalling on behavioural processes to better understand potential
• Link microbiome modulation to disease outcomes and design clinical trials for noncommunicable disease taking this into account

• Explore how AOBiome Therapeutics’ recent metabolomic and preclinical work is shaping a deeper understanding of therapeutic action in dermatological indications
• Share lessons learned from bridging mechanistic hypotheses with clinical trial design to improve signal detection and separate from placebo
• Discuss how mechanistic clarity can inform formulation and delivery strategies, and open doors to new indications

• Challenge assumptions around clinical endpoints and trial design to improve translational success
• Address cost-of-goods and production scalability to unlock sustainable development pathways
• Reframe the probiotic–drug divide to clarify modality, mechanism, and market potential

• Highlight macroeconomic pressures driving renewed interest in neurodegenerative and behavioural health innovation
• Explore how microbiome innovators can tailor value propositions to attract pharma, public sector and philanthropic partners
• Identify collaboration models that bridge lifestyle, food, and therapeutic approaches for real-world impact

• Highlight data-driven milestones that attract funding to unlock capital
• Structure deals to balance risk and reward for early-stage ventures to improve term-sheet appeal
• Position platforms for scalability and exit potential to attract strategic investment

This dynamic session offers a platform for early-stage microbiome companies to pitch their technologies to a panel of investors, pharma scouts, and industry experts. Designed to foster visibility, feedback, and potential partnerships, each presentation is followed by live commentary and audience engagement.